ClinicalTrials.gg
RecruitingNCT06752616Updated Jan 1, 2025

Acute Agitation in Emergency Psychiatry

A Phase 2/3 interventional study of Sublingual Dexmedetomidine and Buccal midazolam in Agitation, sponsored by Lone Baandrup. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-01-01.

Primary conditionPsychomotor Agitation(the registry's first term)UnverifiedIs this wrong?The registry often attaches Psychomotor Agitation to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Lone Baandrup · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The purpose of the study is to improve the pharmacological treatment of psychiatric patients with acute agitation.

Read the detailed description

The initial treatment of acute agitation aims to reduce suffering, abort the immediate risk of harm to self or others, and prevent the use of coercive measures such a physical and mechanical restraint. With this research project, we aim to build the initial structure of a visionary platform design and to examine the efficacy, tolerability, and safety of two hitherto under-investigated compounds versus the current standard of care for acutely agitated patients when de-escalation techniques have failed. After obtaining the results of the initial phase, we plan to apply for future funding to maintain and expand the platform design with the addition of relevant experimental arms. The proposed platform design aims to anwer the question What is the best treatment for acutely agitated patients in inpatient psychiatric settings?

02

Conditions studied

  • Agitation

Browse trials for

Keywords

  • Emergency psychiatry
03

In context

Psychomotor Agitation Unverified

231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.

This study's planned enrollment of 132 is above the median of 100 across 188 interventional studies indexed under Psychomotor Agitation.

Browse Psychomotor Agitation studies →

Lead sponsor

Lone Baandrup is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Compared within Psychomotor Agitation, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-64 years
  • Agitation with the need for tranquillization in inpatient psychiatric settings including psychiatric emergency rooms
  • Total score of ≥14 on the PANSS Excited Component (PEC)
  • A score ≥4 on at least 1 of the 5 items of the PEC
  • obtained prior to the occurrence of the emergency

Exclusion criteria

Exclusion Criteria:

  • Involuntary psychiatric admission according to the Danish Mental Health Act
  • Female patients who are breastfeeding
  • Female patients aged \<50 years and unable to perform a negative urine screen for pregnancy and not using safe
  • Body weight \<50 kg
  • Extreme obesity defined as estimated ≥ 40 kg/m2
  • Clinical situations where acute administration of an antipsychotic is preferred to treat acute agitation (in the opinion of the investigator)
  • The patient deemed unwilling or unable to cooperate with study procedures (in the opinion of the investigator)
  • Insufficient language skills that interfere with reading, writing, and providing written in Danish or other available languages (in the opinion of the investigator)
  • Clinical suspicion of for one of the treatment arms
  • Use of benzodiazepines, other sedatives, or antipsychotic drugs in addition to usual treatment (i.e., additional PN sedative prescriptions) in the 4 hours before study treatment
  • Known allergy to any of the study medications
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Sublingual dexmedetomidine

    Drug: Sublingual Dexmedetomidine

  • Experimental
    Buccal midazolam

    Drug: Buccal midazolam

  • Active comparator
    Oral lorazepam

    Drug: Oral lorazepam

Interventions

06

What researchers measure

Primary outcomes

  1. The Excited Component of the Positive and Negative Syndrome Scale (PEC)

    The Excited Component of the Positive and Negative Syndrome Scale (PEC) consists of 5 clinician-rated items associated with agitation from the Positive and Negative Syndrome Scale (PANSS). Scores range from 5 to 35. Higher is worse.

    Time frame: 60 minutes

Secondary outcomes

  1. PEC score earliest time with difference

    The earliest time where a statistically significant difference in agitation is apparent as measured by change from baseline PEC score (change from pre- to post-dose PEC score at 30, 60, 90, and 120 minutes)

    Time frame: 30, 60, 90, and 120 minutes

  2. Tranquillized or asleep

    Proportion tranquillized or asleep (measured as ≤4 on the BARS\*\*) by 30, 60, 90, and 120 minutes post-dose

    Time frame: 30, 60, 90, and 120 minutes post-dose

  3. Physical restraint

    Proportion physically restrained from administration to 12 hours post-dose

    Time frame: 12 hours post-dose

  4. Mechanical restraint

    Proportion mechanically restrained from administration to 12 hours post-dose

    Time frame: 12 hours post-dose

  5. Rescue medication

    Proportion given rescue medication 4-12 hours post-dose

    Time frame: 4-12 hours post-dose

  6. Patient-reported satisfaction

    Patient-reported satisfaction measured using 4 items from the Treatment Satisfaction Questionnaire for Medication II. Each item is answered on a 7-point Likert scale from 1 (extremely dissatisfied) to 7 (extremely satisfied). Score range is from 4 to 28. Higher is better.

    Time frame: From 2 to 24 hrs post-dose when the participant is able to cooperate

07

Study locations

1 of 1 sites recruiting
  • Mental Health Center Copenhagen, Bispebjerg
    Copenhagen N, 2400, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The study protocol will be available in the CTIS. After publication of primary and secondary outcomes, IPD will be handed over to the Danish National Archives where data will be archived for 25 years. IPD will be shared upon reasonable reuqest after publication of primary and secondary outcomes.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2024
First posted
Dec 30, 2024
StartActual
Dec 30, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jan 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06752616
Lead sponsor
Lone Baandrup
Collaborators
Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Capital Region's Pharmacy (Region Hovedstadens Apotek), Marielundvej 25, 2730 Herlev, Denmark
Responsible party
Lone Baandrup (Head of Clinic, clinical associate research professor, University of Copenhagen) — Sponsor-investigator
First posted
Dec 30, 2024
Start date
Dec 30, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 1, 2025

Study contacts

Lone Baandrup, MD, DMSc
Contact
lone.baandrup@regionh.dk
00 45 91165903
Marie Vang Jensen, MD
Contact
marie.said.vang.jensen@regionh.dk
0045 6199 7358
Lone Baandrup, MD, DMSc
principal investigator · Mental Health Center Copenhagen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Midazolam

Start the discussion